Trial Profile
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Valemetostat (Primary)
- Indications Adult T-cell leukaemia-lymphoma; B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 12 Dec 2023 Results( At the primary trial cutoff (Dec 31, 2022), n=90) presented at the 65th American Society of Hematology Annual Meeting and Exposition, reporting primary clinical outcomes for the subgroup of pts in J101 with R/R B-NHLs, including DLBCL and FL.
- 12 Dec 2023 Primary Results(data cutoff (Dec 31, 2022, n=71 for pts in J101 with R/R T-NHLs ) assessing efficacy and safety Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Dec 2023 According to Daiichi Sankyo media release, data from this trial will be presented at the American Society of Hematology meeting 2023.